Laboratoires Pierre Fabre SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Published : Dec-2017

No. of Pages : 84

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2011 to YTD 2017 12
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17
Pierre Fabre Acquires Desogestrel from Helm Medical 18
Pierre Fabre Acquires Clareal from Helm Medical 19
Pierre Fabre Acquires Batrafen Shampooing Assets from Sanofi 20
Partnerships 21
Pierre Fabre Enters into Distribution Agreement with Medinova 21
Institut Curie Enters into Agreement with Pierre Fabre 22
Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 23
Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 24
Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 25
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 26
Pierre Fabre Pharma Enters into Co-Marketing Agreement with Grupo Biotoscana 27
Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28
Evotec Partners with Pierre Fabre Labs 29
Pierre Fabre Partners with VibioSphen 30
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32
Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33
Pierre Fabre Medicament Partners with Inserm Transfert 34
Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35
Pierre Fabre Partners with Biomax Informatics 36
AbCheck Expands Research Agreement with Pierre Fabre Pharma 37
Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38
Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39
AbCheck Enters Into Research Agreement With Pierre Fabre 40
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42
Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44
Pierre Fabre Enters into Agreement with Geiser Pharma 45
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46
Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47
ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48
Licensing Agreements 49
Substipharm Enters into Licensing Agreement with Pierre Fabre 49
Pierre Fabre Enters into Licensing Agreement with Hill Derma 50
Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 51
Darya-Varia Enters into Licensing Agreement with Pierre Fabre 52
Pierre Fabre Enters into Licensing Agreement with Lonza 53
Pierre Fabre Enters into Licensing Agreement with Lonza 54
Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 55
Pierre Fabre Enters into Licensing Agreement with Medis 56
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 57
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 58
Pierre Fabre Enters into Licensing Agreement with PLEURAN 59
Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 60
Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 61
Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 62
Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 63
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 64
Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 65
Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 66
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 67
Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 68
Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 69
Pierre Fabre Enters into Licensing Agreement with Losan Pharma 70
Pierre Fabre Enters into Licensing Agreement with Fidia Farmaceutici 71
MediGene Enters Into Licensing Agreement With Pierre Fabre For Veregen 72
Equity Offering 73
TargeOn Raises Funds through Private Placement of Shares 73
Asset Transactions 74
Amatsigroup Acquires R&D Center from Pierre Fabre Labs 74
Acquisition 75
Pierre Fabre Sells 6% Stake In Boiron For US$42 Million 75
Laboratoires Pierre Fabre SA - Key Competitors 76
Laboratoires Pierre Fabre SA - Key Employees 77
Laboratoires Pierre Fabre SA - Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Affiliate 81
Recent Developments 82
Product News 82
May 09, 2016: Matwin And Pierre Fabre Fund For Innovation Strengthen Their Partnership To Boost The Development Of Innovative Projects In Oncology 82
Other Significant Developments 83
Oct 10, 2017: Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates 83
Appendix 84
Methodology 84
About GlobalData 84
Contact Us 84
Disclaimer 84

List of Tables
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Laboratoires Pierre Fabre SA, Deals By Therapy Area, 2011 to YTD 2017 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2011 to YTD 2017 12
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 13
Pierre Fabre Pharma Acquires Promising Assets from Igenica Biotherapeutics 17
Pierre Fabre Acquires Desogestrel from Helm Medical 18
Pierre Fabre Acquires Clareal from Helm Medical 19
Pierre Fabre Acquires Batrafen Shampooing Assets from Sanofi 20
Pierre Fabre Enters into Distribution Agreement with Medinova 21
Institut Curie Enters into Agreement with Pierre Fabre 22
Laboratoires Pierre Fabre Enters into Distribution Agreement with BMG Pharma 23
Fine Foods & Pharma Enters into Distribution Agreement with Pierre Fabre 24
Laboratoires Pierre Fabre Enters into Research Agreement with H-Immune 25
Laboratoires Pierre Fabre Enters into Licensing Agreement with PIQUR Therapeutics 26
Pierre Fabre Pharma Enters into Co-Marketing Agreement with Grupo Biotoscana 27
Pierre Fabre Pharma Enters into Partnership with Yale School of Medicine 28
Evotec Partners with Pierre Fabre Labs 29
Pierre Fabre Partners with VibioSphen 30
Pierre Fabre Medicament Enters into Agreement with Pfizer for Toviaz 31
Pierre Fabre Enters into Co-Development Agreement with Array BioPharma 32
Cellectar Biosciences Extends Agreement with Pierre Fabre Lab 33
Pierre Fabre Medicament Partners with Inserm Transfert 34
Pierre Fabre Medicament Enters into Agreement with Ecole Polytechnique Federale de Lausanne 35
Pierre Fabre Partners with Biomax Informatics 36
AbCheck Expands Research Agreement with Pierre Fabre Pharma 37
Pierre Fabre Enters into Co-Promotion Agreement with Laboratoires Thea 38
Pierre Fabre Enters into Distribution Agreement with Laboratorios Vinas for Molusderm 39
AbCheck Enters Into Research Agreement With Pierre Fabre 40
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 41
Redx Pharma Enters into Research Agreement with Pierre Fabre Labs 42
Laboratoires Pierre Fabre Enters into Partnership with UPMC and CNRS 43
Pierre Fabre Enters into Agreement with Roche for NeoRecormon 44
Pierre Fabre Enters into Agreement with Geiser Pharma 45
Pierre Fabre Medicament Enters Into Co-Promotion Agreement With AstraZeneca For Zoladex 46
Merz Enters Into Co-Marketing Agreement With Pierre Fabre For Injectable Glytone 47
ADVENTRX Pharma and Pierre Fabre Medicament Enter into Agreement for ANX-188 48
Substipharm Enters into Licensing Agreement with Pierre Fabre 49
Pierre Fabre Enters into Licensing Agreement with Hill Derma 50
Fertin Pharma Enters into License and Supply Agreement with Pierre Fabre 51
Darya-Varia Enters into Licensing Agreement with Pierre Fabre 52
Pierre Fabre Enters into Licensing Agreement with Lonza 53
Pierre Fabre Enters into Licensing Agreement with Lonza 54
Fertin Pharma Enters into License, Distribution and Supply Agreement with Pierre Fabre 55
Pierre Fabre Enters into Licensing Agreement with Medis 56
Pierre Fabre Pharma Enters into Licensing Agreement with Addex Therapeutics 57
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 58
Pierre Fabre Enters into Licensing Agreement with PLEURAN 59
Pierre Fabre Enters into Licensing Agreement with Laboratoire Top Pharm 60
Pierre Fabre Enters into Licensing Agreement with Alpex Pharma 61
Pierre Fabre Enters into Licensing Agreement with Hermes Pharma 62
Pierre Fabre Enters into Licensing Agreement with Bioiberica for Tendoactive 63
Aurigene Discovery Technologies Enters Into Licensing Agreement With Pierre Fabre For AUNP-12 64
Pierre Fabre Enters into Licensing Agreement with Disphar International for Naproxen 65
Pierre Fabre Enters into Licensing Agreement with Laboratoires Juvise Pharma for Etumina 66
Neurolixis Enters Into Licensing Agreement With Pierre Fabre Medicament 67
Pierre Fabre Enters Into Licensing Agreement With Maruho For Infant Hemangiomas Treatment 68
Pierre Fabre Extends Licensing Agreement with Catalent France for Curacne 69
Pierre Fabre Enters into Licensing Agreement with Losan Pharma 70
Pierre Fabre Enters into Licensing Agreement with Fidia Farmaceutici 71
MediGene Enters Into Licensing Agreement With Pierre Fabre For Veregen 72
TargeOn Raises Funds through Private Placement of Shares 73
Amatsigroup Acquires R&D Center from Pierre Fabre Labs 74
Pierre Fabre Sells 6% Stake In Boiron For US$42 Million 75
Laboratoires Pierre Fabre SA, Key Competitors 76
Laboratoires Pierre Fabre SA, Key Employees 77
Laboratoires Pierre Fabre SA, Other Locations 78
Laboratoires Pierre Fabre SA, Subsidiaries 79
Laboratoires Pierre Fabre SA, Affiliate 81

List of Figures
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 8
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Laboratoires Pierre Fabre SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Laboratoires Pierre Fabre SA, Medical Devices Deals, 2011 to YTD 2017 12

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Laboratoires Pierre Fabre SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027